Expansion Therapeutics CEO and leadership

President and CEO of Expansion Therapeutics, a biotechnology company advancing therapies that target a range of serious diseases caused by RNA. Initially focused on expansion repeat disorders, a set of ~30 genetic diseases including myotonic dystrophy type 1 (DM1), the most frequent cause of adult onset muscular dystrophy. Proven track record in discovering and developing disease modifying small molecule drugs to treat genetically defined diseases. Co-founder and former Chief Scientific Officer of X4 Pharmaceuticals and co-inventor of its lead drug candidate, mavorixafor. Leadership roles in drug discovery and development at Lysosomal Therapeutics and co-inventor of LTI-291, a CNS drug in clinical development for Parkinson’s disease. Former Interim Head of Small Molecule Discovery at Genzyme and part of the executive team at AnorMED, which was acquired by Genzyme in 2006. Instrumental in the development of two FDA approved drugs: plerixafor, a CXCR4-targeted stem cell mobilizer, and ertapenem, an anti-bacterial. Ph.D. in synthetic organic chemistry from the University of British Columbia; completed postdoctoral fellowships at the University of Oxford and Ohio State University.

President and CEO of Expansion Therapeutics, a biotechnology company advancing therapies that target a range of serious diseases caused by RNA. Initially focused on expansion repeat disorders, a set of ~30 genetic diseases including myotonic dystrophy type 1 (DM1), the most frequent cause of adult onset muscular dystrophy. Proven track record in discovering and developing disease modifying small molecule drugs to treat genetically defined diseases. Co-founder and former Chief Scientific Officer of X4 Pharmaceuticals and co-inventor of its lead drug candidate, mavorixafor. Leadership roles in drug discovery and development at Lysosomal Therapeutics and co-inventor of LTI-291, a CNS drug in clinical development for Parkinson’s disease. Former Interim Head of Small Molecule Discovery at Genzyme and part of the executive team at AnorMED, which was acquired by Genzyme in 2006. Instrumental in the development of two FDA approved drugs: plerixafor, a CXCR4-targeted stem cell mobilizer, and ertapenem, an anti-bacterial. Ph.D. in synthetic organic chemistry from the University of British Columbia; completed postdoctoral fellowships at the University of Oxford and Ohio State University.

President and CEO of Expansion Therapeutics, a biotechnology company advancing therapies that target a range of serious diseases caused by RNA. Initially focused on expansion repeat disorders, a set of ~30 genetic diseases including myotonic dystrophy type 1 (DM1), the most frequent cause of adult onset muscular dystrophy. Proven track record in discovering and developing disease modifying small molecule drugs to treat genetically defined diseases. Co-founder and former Chief Scientific Officer of X4 Pharmaceuticals and co-inventor of its lead drug candidate, mavorixafor. Leadership roles in drug discovery and development at Lysosomal Therapeutics and co-inventor of LTI-291, a CNS drug in clinical development for Parkinson’s disease. Former Interim Head of Small Molecule Discovery at Genzyme and part of the executive team at AnorMED, which was acquired by Genzyme in 2006. Instrumental in the development of two FDA approved drugs: plerixafor, a CXCR4-targeted stem cell mobilizer, and ertapenem, an anti-bacterial. Ph.D. in synthetic organic chemistry from the University of British Columbia; completed postdoctoral fellowships at the University of Oxford and Ohio State University.